ADA-SCID - Competitive Landscape and Market Insight, 2018
This report can be delivered to the clients within 24 hours
'ADA-SCID - Competitive Landscape and Market Insight, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved. The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, ADA-SCID Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.
Products covered by Phase
Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
'ADA-SCID - Competitive Landscape and Market Insight, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this indication. The report provides the detailed analysis of marketed as well as pipeline products along with the companies involved. The report covers the Market Scenario till 2027, Attribute analysis, Product Potential Analysis, ADA-SCID Market Evolution, and Unmet Needs. This report further provides comprehensive Insight about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis along with forecasted sales for upcoming launches.
Products covered by Phase
- Phase III and Phase II
- IND
Pipeline analysis of the therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE
- The report provides competitive pipeline landscape of ADA-SCID
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for ADA-SCID
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the ADA-SCID pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for ADA-SCID and also provide company profiling
- Pipeline products coverage based on various stages of development ranging from late stage till IND stage
- Provides attribute analysis Report also covers the Attribute analysis, Product Potential Analysis, ADA-SCID Market Evolution, Market Scenario, and Unmet Needs
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Establish a comprehensive understanding of the current pipeline scenario across ADA-SCID to formulate effective R&D strategies
- Assess challenges and opportunities that influence ADA-SCID R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Devise corrective measures for pipeline projects by understanding ADA-SCID pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for ADA-SCID to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
- Gaining a full picture of the Competitive Landscape for Evidence based Decisions
Overview
Severe Combined Immunodeficiency (SCID)
Adenosine Deaminase - Severe Combined Immunodeficiency (ADA-SCID)
History of ADA-SCID
Pathogenesis of ADA-SCID
Inheritance pattern of ADA-SCID
Symptoms of ADA-SCID
Diagnosis of ADA-SCID
Treatment of ADA-SCID
Unmet needs
Epidemiology- 7MM
Assumptions and Rationale
Incidence of ADA-SCID in 7MM
Prevalence of ADA-SCID in 7MM
Marketed Products
Adagen: Leadiant Biosciences
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages and Disadvantages
Safety and Efficacy
Product Profile
Forecasted Sales
(The list continues)
Competitive Landscape
Additional Research
Non-integrative replicative episomal lentiviral vector technology
Market Assessment
7MM MARKET SIZE
Market Evolution
Attribute Analysis
Analysis
Product Potential Analysis
Appendix
Severe Combined Immunodeficiency (SCID)
Adenosine Deaminase - Severe Combined Immunodeficiency (ADA-SCID)
History of ADA-SCID
Pathogenesis of ADA-SCID
Inheritance pattern of ADA-SCID
Symptoms of ADA-SCID
Diagnosis of ADA-SCID
Treatment of ADA-SCID
Unmet needs
Epidemiology- 7MM
Assumptions and Rationale
Incidence of ADA-SCID in 7MM
Prevalence of ADA-SCID in 7MM
Marketed Products
Adagen: Leadiant Biosciences
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages and Disadvantages
Safety and Efficacy
Product Profile
Forecasted Sales
(The list continues)
Competitive Landscape
Additional Research
Non-integrative replicative episomal lentiviral vector technology
Market Assessment
7MM MARKET SIZE
Market Evolution
Attribute Analysis
Analysis
Product Potential Analysis
Appendix
LIST OF TABLES
Table 1: 7MM, ADA-SCID Incidence, 2015-2027
Table 2: 7MM, ADA-SCID Prevalence, 2015-2027
Table 3: 7MM Market Size (in USD million)
Table 1: 7MM, ADA-SCID Incidence, 2015-2027
Table 2: 7MM, ADA-SCID Prevalence, 2015-2027
Table 3: 7MM Market Size (in USD million)
LIST OF FIGURES
Figure 1: Timeline of Advances in SCID
Figure 2: Pathogenesis of ADA-SCID
Figure 3: Inheritance pattern of ADA-SCID
Figure 4: Treatment Strategies for ADA-SCID
Figure 5: Treatment Algorithm for ADA-SCID
Figure 9: 7MM, ADA-SCID Incidence, 2015-2027
Figure 10: 7MM, ADA-SCID Prevalence, 2015-2027
Figure 7: Adagen, Forecasted Sales, 2015-2027
Figure 8: Drug 2, Forecasted Sales, 2016-2027
Figure 6: Drug 3, Market Size, 2022-2027
Figure 11:7MM Overall Market Size
Figure 12: 7MM Overall Market Size
Figure 1: Timeline of Advances in SCID
Figure 2: Pathogenesis of ADA-SCID
Figure 3: Inheritance pattern of ADA-SCID
Figure 4: Treatment Strategies for ADA-SCID
Figure 5: Treatment Algorithm for ADA-SCID
Figure 9: 7MM, ADA-SCID Incidence, 2015-2027
Figure 10: 7MM, ADA-SCID Prevalence, 2015-2027
Figure 7: Adagen, Forecasted Sales, 2015-2027
Figure 8: Drug 2, Forecasted Sales, 2016-2027
Figure 6: Drug 3, Market Size, 2022-2027
Figure 11:7MM Overall Market Size
Figure 12: 7MM Overall Market Size
